Banque Cantonale Vaudoise Bei Gene, Ltd. Transaction History

Banque Cantonale Vaudoise

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 17, 2022	BUY	$131.8 - $202.24 $395 - $606	3 Added 1.36%	223 $30,000
Q2 2022 Aug 02, 2022	BUY	$121.11 - $216.05 $5,813 - $10,370	48 Added 27.91%	220 $36,000
Q1 2022 May 09, 2022	SELL	$146.52 - $269.56 $144,908 - $266,594	-989 Reduced 85.19%	172 $32,000
Q3 2021 Oct 29, 2021	SELL	$249.6 - $403.14 $307,756 - $497,071	-1,233 Reduced 51.5%	1,161 $421,000
Q2 2021 Aug 11, 2021	SELL	$292.75 - $367.01 $3,805 - $4,771	-13 Reduced 0.54%	2,394 $821,000
Q1 2021 May 11, 2021	BUY	$260.64 - $382.12 $366,720 - $537,642	1,407 Added 140.7%	2,407 $838,000
Q1 2020 May 14, 2020	BUY	$121.84 - $173.19 $121,840 - $173,190	1,000 New	1,000 $123,000

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Banque Cantonale Vaudoise, based on Form 13F filings with the SEC.

Stay updated on Banque Cantonale Vaudoise with notifications on news.